{"database": "lobbying", "table": "lobbying_activities", "rows": [[2818051, "57caf115-24b0-4801-bddf-169806559ff9", "Q2", "CRISPR THERAPEUTICS, INC.", 401105184, "CRISPR THERAPEUTICS, INC.", 2022, "second_quarter", "MED", "General issues related to FDA approval policies for cell and gene therapies. Policies related to the reauthorization of the Prescription Drug User Fee Act.", "HOUSE OF REPRESENTATIVES,SENATE", null, 90000, 0, 0, "2022-07-13T12:23:56-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2818051"], "units": {}, "query_ms": 45.68681702949107, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}